甲磺酸阿帕替尼片用于标准治疗失败后卵巢癌治疗的有效性和安全性

Efficacy and safety of apatinib mesylate treatment for ovarian cancer after failure of the standard treatment

目的:观察甲磺酸阿帕替尼用于标准治疗失败后卵巢癌的有效性和安全性,为多线耐药的卵巢癌患者提供一种治疗方式。方法:选取2015年6月至2018年3月二线及二线后化疗失败的晚期卵巢癌患者26例,口服甲磺酸阿帕替尼后观察疗效及毒副反应。结果:1例患者CR,17例患者PR,2例患者SD,6例患者PD,客观有效率69%,疾病控制率77%,中位PFS达4.3个月。患者总体耐受性良好,常见的不良反应为1-3级的胃肠道反应,包括腹痛、恶心及呕吐,其中以腹痛最为常见。结论:对于经标准治疗失败后的晚期卵巢癌患者,阿帕替尼具有良好的疗效和安全性。

Objective:To observe the effect of apatinib mesylate combined chemotherapy treatment for ovarian cancer patients with standard treatment failed,to provide an alternative therapy for multi-line therapy resistant ovarian cancer patients.Methods:26 patients with advanced ovarian cancer who failed at least two lines of prior chemotherapy from June 2015 to March 2018 were selected.To observe the efficacy and adverse reactions of these patients after oral apatinib mesylate.Results:One patient was complete remission,17 patients were partial remission,2 patients were in stable disease and progression of disease was observed in 6 patients.Theobjective response rate was 69%.The disease control rate was 77%.The median progression free survival(PFS) was 4.3 months.Overall apatinib treatment was well tolerated.The common adverse events were grade 1 to 3 gastrointestinal reactions,including abdominal pain,nausea and vomiting,and the abdominal pain was the most common.Conclusion:Apatinib mesylate is effective and tolerable for patients with advanced ovarian cancer who failed the standard treatment.